These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 785578)

  • 21. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 23. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
    Albani C; Buck A
    Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
    [No Abstract]   [Full Text] [Related]  

  • 24. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
    Liu DK
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980; 13(3):147-50. PubMed ID: 7438902
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH; Lees AJ; Stern GM
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
    Hayek J
    Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336
    [No Abstract]   [Full Text] [Related]  

  • 33. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 34. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 36. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
    Williams BO; Carlyle D
    Curr Med Res Opin; 1979; 6(1):1-7. PubMed ID: 378553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 40. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.